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Tissue-specific alterations of methyl group metabolism with DNA
hypermethylation in the Zucker (type 2) diabetic fatty rat.
Abstract
BackgroundAltered methyl group and homocysteine metabolism were tissue-specific, persistent, and
preceded hepatic DNA hypomethylation in type 1 diabetic rats. Similar metabolic perturbations have been
shown in the Zucker (type 2) diabetic fatty (ZDF) rat in the pre-diabetic and early diabetic stages, but tissue
specificity and potential impact on epigenetic marks are unknown, particularly during pathogenesis.
Methods ZDF (fa/fa) and lean (+/?) control rats were killed at 12 and 21 weeks of age, representing early
and advanced diabetic conditions. Blood and tissues were analysed with respect to methyl group and
homocysteine metabolism, including DNA methylation.
Results At 12 weeks, hepatic glycine N-methyltransferase (GNMT), methionine synthase, and cystathionine
β-synthase (CBS) activity and/or abundance were increased in ZDF rats. At 21 weeks, GNMT activity was
increased in liver and kidney; however, only hepatic CBS protein abundance (12 weeks) and betaine-
homocysteine S-methyltransferase mRNA expression (21 weeks) were significantly elevated (78 and 100%,
respectively). Hepatic phosphatidylethanolamine N-methyltransferase expression was also elevated in the
ZDF rat. Homocysteine concentrations were decreased in plasma and kidney, but not in liver, at 12 and 21
weeks. In contrast to hepatic DNA hypomethylation in the type 1 diabetic rat, genomic DNA was
hypermethylated at 12 and 21 weeks in the liver of ZDF rats, concomitant with an increase in DNA
methyltransferase 1 expression at 21 weeks.
ConclusionsThe pathogenesis of type 2 diabetes in the ZDF rat was associated with tissue and disease stage-
specific aberrations of methyl group and homocysteine metabolism, with persistent hepatic global DNA
hypermethylation.
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Abstract: 
Background   Altered methyl group and homocysteine metabolism 
was tissue-specific, persistent, and preceded hepatic DNA 
hypomethylation in type 1 diabetic rats.  Similar metabolic 
perturbations have been shown in the Zucker (type 2) diabetic fatty 
(ZDF) rat in the pre- and early diabetic stages, but tissue specificity 
and potential impact on epigenetic marks are unknown, particularly 
during pathogenesis. 
Methods   ZDF (fa/fa) and lean (+/?) control rats were killed at 12 
and 21 wk of age, representing early and advanced diabetic 
conditions.  Blood and tissues were analyzed with respect to methyl 
group and homocysteine metabolism, including DNA methylation. 
Results   At 12 wk, hepatic glycine N-methyltransferase (GNMT), 
methionine synthase, and cystathionine β-synthase (CBS) activity 
and/or abundance were increased in ZDF rats.  At 21 wk, GNMT 
activity was increased in liver and kidney; however, only hepatic 
CBS protein abundance (12 wk) and betaine-homocysteine S-
methyltransferase mRNA expression (21 wk) were significantly 
elevated (78 and 100%, respectively).  Hepatic 
phosphatidylethanolamine N-methyltransferase expression was also 
elevated in the ZDF rat.  Homocysteine concentrations were 
decreased in plasma and kidney, but not in liver, at 12 and 21 wk. 
 In contrast to hepatic DNA hypomethylation in the type 1 diabetic 
rat, genomic DNA was hypermethylated at 12 and 21 wk in the liver 
of ZDF rats, concomitant with an increase in DNMT1 expression at 
21 wk.   
Conclusions  The pathogenesis of type 2 diabetes in the ZDF rat 
was associated with tissue- and disease stage-specific aberrations 
of methyl group and homocysteine metabolism, with persistent 
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Abstract 
Background   Altered methyl group and homocysteine metabolism was tissue-specific, 
persistent, and preceded hepatic DNA hypomethylation in type 1 diabetic rats.  Similar metabolic 
perturbations have been shown in the Zucker (type 2) diabetic fatty (ZDF) rat in the pre- and 
early diabetic stages, but tissue specificity and potential impact on epigenetic marks are 
unknown, particularly during pathogenesis. 
Methods   ZDF (fa/fa) and lean (+/?) control rats were killed at 12 and 21 wk of age, 
representing early and advanced diabetic conditions.  Blood and tissues were analyzed with 
respect to methyl group and homocysteine metabolism, including DNA methylation. 
Results   At 12 wk, hepatic glycine N-methyltransferase (GNMT), methionine synthase, 
and cystathionine β-synthase (CBS) activity and/or abundance were increased in ZDF rats.  At 
21 wk, GNMT activity was increased in liver and kidney; however, only hepatic CBS protein 
abundance (12 wk) and betaine-homocysteine S-methyltransferase mRNA expression (21 wk) 
were significantly elevated (78 and 100%, respectively).  Hepatic phosphatidylethanolamine N-
methyltransferase expression was also elevated in the ZDF rat.  Homocysteine concentrations 
were decreased in plasma and kidney, but not in liver, at 12 and 21 wk.  In contrast to hepatic 
DNA hypomethylation in the type 1 diabetic rat, genomic DNA was hypermethylated at 12 and 
21 wk in the liver of ZDF rats, concomitant with an increase in DNMT1 expression at 21 wk.   
Conclusions  The pathogenesis of type 2 diabetes in the ZDF rat was associated with 
tissue- and disease stage-specific aberrations of methyl group and homocysteine metabolism, 
with persistent hepatic global DNA hypermethylation. 
 
Key Words:  diabetes; ZDF rat; methyl group metabolism; DNA methylation; GNMT 
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Introduction 
It is estimated that over 12% of the U.S. population is afflicted with diabetes, with type 2 
diabetes representing 95% of all cases [1].  Diabetes has recently been identified as a condition 
that can profoundly alter methyl group and homocysteine metabolism [2,3].  There are three 
primary pathways involved in the metabolism of methyl groups and homocysteine: 
transmethylation, remethylation via folate/B12-dependent or –independent mechanisms, and 
transsulfuration (Figure 1). For transmethylation reactions, methionine is activated to S-
adenosylmethionine (SAM), which serves as the universal methyl group donor for numerous 
methyltransferases, resulting in the methylation of substrates such as nucleic acids, lipids, and 
proteins.  All SAM-dependent methyltransferase reactions result in the generation of 
homocysteine, which can be remethylated back to methionine using methyl groups donated by 
either 5-methyltetrahydrofolate (5-CH3-THF) or betaine.  For folate-dependent remethylation, 
the B12-dependent enzyme methionine synthase (MS) utilizes a methyl group from 5-CH3-THF, 
whereas betaine-homocysteine S-methyltransferase (BHMT) catalyzes the folate-independent 
remethylation of homocysteine using betaine, a methyl group donor derived from the oxidation 
of choline.  Alternatively, homocysteine can be catabolized through the transsulfuration pathway 
to cysteine, beginning with its irreversible conversion to cystathionine by cystathionine β-
synthase (CBS).    
We, and others, have previously shown that an acute diabetic condition alters methyl 
group and homocysteine metabolism [4-9].  Diabetes induced hepatic protein abundance and 
activity of glycine N-methyltransferase (GNMT) and phosphatidylethanolamine N-
methyltransferase (PEMT), enzymes that have important roles in regulation of methyl groups 
and homocysteine.  GNMT is proposed to be a regulator of the transmethylation potential via 
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maintenance of the SAM:S-adenosylhomocysteine (SAH) ratio, whereas PEMT catalyzes the 
sequential trimethylation of phosphatidylethanolamine to phosphatidylcholine and is purported 
to be the greatest consumer of SAM-derived methyl groups [10].  Induction of BHMT and CBS 
are also consistently observed in diabetic or glucocorticoid-treated conditions [4,5,7-9,11,12], 
whereas the effect of diabetes on MS is not consistent.  Taken together, these metabolic 
alterations result in hypohomocysteinemia in the early diabetic condition.  Importantly, similar 
metabolic aberrations have been observed in both type 1 and type 2 diabetic rat models, as well 
as diabetic patients [4,5,7-9,13,14] 
Progression of diabetes is associated with the development of secondary complications, 
including cardiovascular disease, nephropathy, neuropathy, and retinopathy.   As renal 
dysfunction in diabetic patients develops, there is a shift from hypo- to hyperhomocysteinemia 
and suppression of 5,10-methylenetetrahydrofolate reductase (MTHFR) activity  that correlates 
with severity of nephropathy [14,15].  Type 2 diabetics with nephropathy also have decreased 
flux through the transsulfuration pathway, which likely contributes to a reduction in metabolic 
homocysteine clearance [16].  Using the streptozotocin (STZ)-treated rat, we have reported 
tissue-specific and sustained alterations of hepatic methyl group/ homocysteine metabolism 
appeared to result in a functional methyl deficient condition, as evidenced by hepatic genomic 
DNA hypomethylation [7]).   
 The progression of type 2 diabetes from prediabetes to the early diabetic state in the 
Zucker (type 2) diabetic fatty (ZDF) rat with respect to methyl group and homocysteine 
metabolism has been reported [9]; however, the more advanced diabetic condition has not been 
fully characterized.  Moreover, the consequences of perturbed methyl group metabolism on DNA 
methylation has not been examined as a function of type 2 diabetes progression.  Similar 
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alterations in methyl group metabolism have been reported when comparing type 1 and type 2 
diabetes [14].   Therefore, we hypothesized that ZDF rats with advanced type 2 diabetes would 
have perturbed methyl group and homocysteine metabolism, including chronic upregulation of 
GNMT, and develop a methyl-deficient condition similar to type 1 diabetes [7].  Furthermore, 
due to the functional methyl deficiency, we hypothesized that the animals would have abnormal 
DNA methylation and expression of epigenetic regulatory proteins, similar to that observed in 
the STZ-diabetic rat [7] or rats fed methyl-deficient diets [16].  To date, abnormal DNA 
methylation as a function of type 2 diabetes has not been examined or reported.  
 
Materials and Methods 
 Chemicals and reagents 
Reagents were obtained as follows:  3T3 fully methylated DNA, BssHII, HpaII, and MspI 
restriction enzymes, New England Biolabs, Inc. (Ipswich, MA); 5-[3H]-dCTP, MP Biomedicals 
(Solon, OH); enhanced chemiluminescence Western blotting detection reagents and 5-[14C]-
methyl-THF, Amersham/GE Healthcare (Piscataway, NJ); CBS antibody (H-300, sc-67154), 
goat anti-rabbit and goat anti-chicken horseradish peroxidase secondary antibodies, Santa Cruz 
Biotechnology, Inc (Santa Cruz, CA); and S-adenosyl-L-[3H]-methionine, Perkin Elmer Life 
Sciences (Waltham, MA).  All other reagents were of analytical grade. 
Animals 
All animal protocols were approved by and conducted in accordance with the guidelines set forth 
by the Iowa State University Institutional Animal Care and Use Committee.  For the first study, 
male rats were obtained at 11 wk of age, allowed to acclimate for 1 wk, and killed at 12 wk of 
age.  For the second study, male rats were obtained at 10 wk of age and killed at 21 wk of age.  
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Each study utilized six lean (ZDF/Gmi +/?) and six ZDF (ZDF/Gmi fa/fa) rats (Charles River 
Laboratories, Wilmington, MA) kept in individual cages with a 12-h light-dark cycle and given 
ad libitum access to water and Purina 5008 diet.  Following a 12-h fast, rats were anesthetized by 
intraperitoneal injection with ketamine: xylazine (90: 10 mg/kg body weight, respectively), 
whole blood samples were collected by cardiac puncture, and blood glucose levels were 
immediately assessed using a glucometer.  Plasma and serum samples were obtained by 
centrifugation and stored at -20°C.  Serum insulin levels were analyzed by Rat/Mouse Insulin 
ELISA Kit (Linco, Inc., St Charles, MO).   Tissues were rapidly removed and a portion of the 
liver was immediately homogenized for preparation of cytosolic extracts as previously described 
[7].  The remainder of the liver and all other tissues were frozen in liquid nitrogen and stored at -
70°C.  The total soluble protein concentration of extracts was determined using the Bradford 
assay with Coomassie Protein Plus Reagent (Thermo Scientific). 
Enzyme assays 
The enzymatic activity of GNMT, PEMT, and MS were determined using radioisotopic assays as 
previously described [5-7,17,18].  Briefly, GNMT and MS activity in the liver, kidney, and heart 
were determined by incubation of cytosolic extracts with reaction mixes containing S-adenosyl-
L-[3H-methyl]-methionine or 5-[14C]-methyl-THF, respectively.  After terminating the reaction, 
the unreacted radiolabeled substrate was removed using activated charcoal or anion exchange 
resin, respectively.  Using microsomal extracts, hepatic PEMT activity was assessed by 
determining the incorporation of S-adenosyl- L-[3H-methyl]-methionine into the lipid fractions.  
Liquid scintillation counting was used to determine radiolabel incorporation for all assays. 
Immunoblotting 
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Relative protein abundance was determined using methods previously described [7] with minor 
modifications.  Proteins were separated using SDS-PAGE and subsequently transferred to 
nitrocellulose.  For assessment of GNMT protein abundance, blots were incubated with an 
affinity-purified chicken antibody (Aves Labs, Inc., Tigard, OR) directed against the peptide 
sequence KER WNR RKE PAF DK (GNMT residues #97-110) diluted 1:40,000 in TTBS/ 10% 
BSA.  CBS primary antibody was prepared 1:400 in TTBS/ 10% BSA, and goat anti-chicken or 
anti-rabbit horseradish peroxidase secondary antibodies were diluted 1:5,000 in TTBS.  
Following incubation with chemiluminescence reagents and subsequent exposure to film, 
relative protein abundance was quantified by densitometric analysis with QuantityOne software 
(Bio-Rad Laboratories, Hercules, CA).  
DNA methylation 
Using the method of Pogribny et al [19] and as described previously [7], digestion of DNA 
followed by cytosine extension was used for assessment of DNA methylation status in liver, 
kidney, and heart tissues.  Global and CpG island DNA methylation were determined by 
digesting 1.0 µg DNA using the methylation-sensitive restriction enzymes HpaII and BssHII, 
respectively.  For the cytosine extension assay, a reaction mixture of the DNA digest, 10X PCR 
Buffer II (without MgCl2), 25 mM MgCl2, 0.5 U Amplitaq DNA Polymerase (Applied 
Biosystems), and [3H]-dCTP was incubated at 55˚C for 1 h.  Following incubation, samples were 
applied to Whatman DE-81 ion exchange filter paper and washed in 0.5 mM sodium phosphate 
buffer (pH 7.0) three times, dried, and 3H incorporation was assessed using liquid scintillation 
counting.  Samples were run in duplicate and reactions using either MspI-digested DNA or 
mouse 3T3 fully-methylated DNA with the appropriate restriction enzyme were used as controls.  
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The degree of genomic methylation fell within the expected range of 70-90% [20] compared to 
the MspI control.  
Real-time RT-PCR 
A 0.1 g sample of frozen liver was preserved in 1.0 mL RNALater-ICE (Ambion, Inc, Austin, 
TX) and subsequently used for RNA isolation using Trizol Reagent (Invitrogen, Carlsbad, CA) 
with TURBO DNA-free (Ambion, Inc.) DNase treatment.  The reverse-transcription assay was 
performed using iScript Select cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) and 
the resulting cDNA was diluted 50-fold for use in the PCR reaction with iQ SYBR Green 
Supermix (Bio-Rad Laboratories).  The specific primers used for RT-PCR (Table 1) were 
designed using PrimerQuest (Integrated DNA Technologies, Inc., Coralville, IA).   Samples were 
run in duplicate, data were normalized to 18S control, and results were analyzed using the 
comparative Ct method.   
Statistical analysis 
For each time point, the mean values of each treatment group (lean vs. ZDF) were subjected to a 
Student’s t test (SigmaStat, SPSS, Chicago, IL).  A Mann-Whitney rank sum test was used when 
normality or equal variance test failed.  Differences were considered significant when P ≤ 0.05 
using a one-tailed test. 
 
Results 
Confirmation of a diabetic condition in ZDF rats 
All ZDF rats were hyperglycemic (blood glucose: 26.2 ± 1.9 and 30.2 ± 0.8 mM) compared to 
control values (blood glucose: 12.1 ± 0.9 and 17.8 ± 1.1 mM) at 12 and 21 wk, respectively.  
Likewise, serum insulin levels were elevated at 12 and 21 wk (0.63 ± 0.10 and 0.81 ± 0.13 
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ng/mL) compared to values (0.32 ± 0.03 and 0.44 ± 0.02 ng/mL), indicating a hyperinsulinemic 
state. 
Perturbation of methyl group metabolism regulatory proteins in the ZDF rat 
Diabetes produced tissue- and time-specific changes in the activity (Table 2) and expression 
(Table 3) of a number of key enzymes involved in methyl group metabolism.  GNMT and PEMT 
are key proteins in the regulation of methyl group and homocysteine balance.  The activity and 
protein abundance of GNMT were elevated in the liver of ZDF rats compared to lean controls at 
both 12 and 21 wk of age (Table 2).  In support of this finding, GNMT mRNA abundance was 
also increased in the liver at 21 wk (Table 3).   Renal GNMT activity was increased at 21 wk 
(Table 2); however, a corresponding increase in renal GNMT protein abundance was not 
observed, suggesting possible post-translational regulation of GNMT activity in the diabetic rat 
kidney.  Contrary to our previous results using the type 1 diabetic rat, hepatic PEMT activity was 
unchanged in the ZDF rat at 12 wk and enzyme activity was decreased at 21 wk (lean vs. ZDF: 
88 ± 10 vs. 62 ± 8 pmol/min·mg protein, P = 0.035).  However, similar to the increase in PEMT 
activity noted in the type 1 diabetic rat (6), there was a trend (P < 0.10) towards increased 
hepatic PEMT mRNA abundance at 12 wk and a statistically significant 73% increase in PEMT 
mRNA abundance in ZDF rat liver at 21 wk (Table 3). 
Removal of homocysteine via folate/B12-dependent and -independent remethylation (MS 
and BHMT, respectively), or catabolism by the transsulfuration pathway (CBS), was 
significantly altered in the ZDF rat that was highly dependent on age and was tissue-specific.  In 
agreement with the type 1 diabetic rat (4), BHMT mRNA abundance was increased in the ZDF 
rat liver at 21 wk (Table 3).  In the early diabetic condition (12 wk), hepatic MS activity was 
significantly increased (Table 2), supported by a similar trend for MS mRNA abundance (Table 
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3); however, no significant differences were observed in the liver at 21 wk, or in renal MS 
activity.  CBS did not show any changes in mRNA abundance (Table 3), but there was a tissue-
specific effect on protein abundance (Table 2).  Similar to observations from the STZ-diabetic rat 
(7), CBS protein abundance was greater in the liver, whereas it was decreased in the kidney 
when ZDF rats were compared to lean controls at 12 wk.  At 21 wk, hepatic CBS abundance was 
reduced in the ZDF rat, and no significant difference was observed in renal CBS protein 
abundance between ZDF and lean rats.  For heart tissue, MS activity was increased and CBS 
abundance was decreased 12% in ZDF rats relative to controls (Table 2) at 21 wk.  In both the 
early and advanced diabetic conditions, cardiac GNMT protein abundance was similar between 
diabetic rats and controls; however, no appreciable cardiac GNMT activity was detected. 
Perturbation of homocysteine balance in the ZDF rat 
Plasma total homocysteine concentrations were decreased 67 and 54% in ZDF rats at 12 and 21 
wk, respectively, compared to the lean controls (Table 4).  There were no changes in the hepatic 
concentration of homocysteine at either time point.  However, homocysteine concentrations in 
the kidney reflected the changes in plasma homocysteine, exhibiting a significant decrease of 63 
and 49% in the ZDF kidney at 12 and 21 wk, respectively.   
DNA hypermethylation and upregulation of DNMT1 in the type 2 diabetic rat liver 
In contrast to the development of hepatic global DNA hypomethylation in the advanced STZ-
diabetic rat (7), global DNA hypermethylation was characteristic of ZDF rat liver at both 12 and 
21 wk (Figure 2).  This effect was specific to genomic DNA in the liver; global DNA changes 
were not observed in the kidney (Figure 2) and heart, nor in CpG island methylation status as 
measured by the overall incorporation of [3H]-dCTP.  DNMT1 mRNA abundance was increased 
95% in the ZDF rat liver at 21 wk (Table 3).  No significant changes were observed in the 
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mRNA abundance of other key nuclear proteins involved in DNA methylation, including DNMT 
3a and 3b, as well as MBD 1,2,3,4 and MeCP2 (data not shown). 
 
Discussion 
Here, we demonstrate that during the progression of type 2 diabetes in the ZDF rat there are 
tissue-specific alterations of methyl group and homocysteine metabolism consistent with type 1 
diabetes [4-7], accompanied by concomitant changes in epigenetic marks, namely the 
methylation of DNA.  However, unlike the effects of the chronic type 1 diabetic condition in 
which we observed hepatic genomic DNA hypomethylation [7], genomic DNA was 
hypermethylated in the ZDF rat liver, even in the early (12 wk) stages of the disease.  In early 
diabetes, both ZDF and type 1-diabetic rat models have been shown to exhibit similar 
perturbations in hepatic methyl group and homocysteine metabolism [4-9], consistent with our 
observations with ZDF rats at 12 wk of age.  The net effect of these metabolic perturbations may 
result in the loss of methyl groups via induction of GNMT and an increase in the flux through the 
transsulfuration pathway, although this was not directly measured.  This might be anticipated 
based on the abundance of evidence supporting GNMT as a regulator of the SAM:SAH ratio 
[22], and the known induction of CBS expression and activity by glucocorticoids and SAM, 
respectively [23,24].  The upregulation of CBS may be a compensatory mechanism for self-
protection of the liver and kidney against the oxidative stress associated with a diabetic 
condition.  CBS activity has been shown to be enhanced under conditions of oxidative stress [25] 
and the antioxidant glutathione, a by-product of the transsulfuration pathway, has been reported 
to be depleted in diabetic tissues [26].  
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It appears that the pathogenesis of type 2 diabetes from 12 to 21 wk results in further 
alterations in methyl group metabolism.  The induction of GNMT at 21 wk was not as robust as 
that observed for 12 wk with only a 19 and 8% increase in activity and protein abundance, 
respectively.  However, there was a significant increase in BHMT mRNA abundance at 21 wk 
that was not observed in the early (12 wk) diabetic condition.  For diabetes, increases in BHMT 
mRNA abundance have previously been associated with increased BHMT activity [12], 
suggesting enhanced homocysteine remethylation.  Interestingly, PEMT was upregulated at the 
mRNA level, whereas PEMT activity was decreased at 21 wk.  Taken together, a decrease in 
production of homocysteine by PEMT and GNMT, combined with an increase in BHMT 
activity, might be expected to contribute to the hypohomocysteinemia that persisted in the 
advanced diabetic state despite no change in CBS protein abundance.  Others have shown that 
diabetes also increases homocysteine catabolism via transsulfuration [9,12].  
The response of the kidney to a diabetic condition appears to be less stringently regulated 
compared to the liver.  Whereas hepatic enzymes relevant to methyl group and homocysteine 
metabolism appear to be regulated at a transcriptional and/or translational level during diabetes 
progression, there was a lesser impact on these enzymes in the kidney.  Thus, a diabetic 
condition appears to have a direct impact on hepatic methyl group metabolism via alterations in 
gene expression, whereas renal methyl group metabolism may reflect the diminished supply of 
methyl groups from the liver.  Renal GNMT activity was only increased in the more advanced 
diabetic state (21 wk) and there were not concomitant increases in protein abundance.  We have 
previously established that GNMT regulation is tissue-specific in response to retinoids [26], as 
well as diabetes [7].  Aside from the increase in GNMT activity, there were no observed 
alternations of other methyl group-related enzymes, nor was DNA methylation status affected in 
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the kidney.  House et al [27] also found a lack of effect of either glucagon treatment or STZ-
diabetes on renal methyl group metabolism, whereas Jacobs et al [8] reported that renal MS and 
MTHFR activities were suppressed by a type 1 diabetic condition.  
Homocysteine balance within a tissue, and subsequently the circulation, reflects the 
collective metabolic routes linked to its production, remethylation, and catabolism.  The liver is 
unique in that it contains the full complement of pathways involved in methyl group metabolism.  
The kidney also exhibits all of the pathways [28]; however, BHMT is expressed at low levels in 
the rat kidney compared to human tissue [29] and MS activity was found not to be quantitatively 
significant [28,30], resulting in transsulfuration being the primary route for removal of 
homocysteine in the kidney.  Homocysteine levels in the ZDF liver were not different from 
controls at 12 or 21 wk, despite decreased homocysteine concentrations in both the plasma and 
kidney.  It is unlikely that the low levels of homocysteine in the kidney are due to increased 
urinary excretion, because this was shown not to be a significant route for homocysteine removal 
in healthy or STZ-diabetic kidneys [8,30].  However, this may be different for the ZDF rat, 
where glomerular filtration rate was elevated at 3 months of age [31].  Thus, the reduction in 
renal and plasma homocysteine concentrations may be the result of increased excretion in the 
ZDF rat model.   The kidney has been shown to contribute significantly to the removal of 
homocysteine from the circulation [32] and data suggests it contains adequate CBS to 
compensate for acute or chronic increases in plasma homocysteine [28].  Taken together, it 
appears that the persistent hypohomocysteinemia observed in type 2 diabetes rat models might 
be due to an irreversible loss of homocysteine via the renal transsulfuration pathway and/ or 
excretion.  In contrast, homocysteine may be remethylated to methionine in the kidney owing to 
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a markedly elevated expression of BHMT in humans compared to the rat, thereby conserving the 
homocysteine moiety and contributing to the eventual development of hyperhomocysteinemia. 
The observation of global DNA hypermethylation in the livers of ZDF rats was 
particularly intriguing and completely divergent from our previous observations in the type 1 
diabetes [7].  Although DNA hypomethylation has been shown to be associated with a number of 
pathological conditions, hypermethylation of DNA can also have deleterious effects.  DNA  
methylation at cytosine residues within CpG dinucleotides is an important modulator of 
chromatin structure, repressor of transposable elements, and regulator of gene expression 
[33,34].  The CpG sequence represents only 1-4% of the genome and this is proposed to be due 
to selection against the sequence due to its high potential for deleterious effects [35].  An 
increase in the levels of 5-methylcytosine elevates the chance of point mutations throughout the 
genome by spontaneous deamination [36], whereby an unmethylated cytosine base is deaminated 
to uracil and deamination of methylated cytosine produces thymine.  If undetected by DNA 
repair enzymes prior to replication, the transition mutation will be maintained and carried on to 
daughter cells, thereby contributing to genomic instability.  Moreover, induction of genomic 
DNA hypermethylation owing to overexpression of DNMT1 was associated with chromosomal 
overcondensation, as well as chromosomal rearrangement and misalignment of sister chromatids 
[37], which could be expected to alter chromosomal segregation during cell division.  Genomic 
hypermethylation has been associated with increased methylation at histone 3 lysine 9 [37], a 
finding that was also observed in lymphocytes from type 1 diabetic patients and associated with 
the promoter regions of a number of genes involved in inflammation, which may contribute to 
the development of secondary complications [38].  Likewise, one of the few reports of genomic 
DNA hypermethylation in clinical studies found that leukocytic DNA hypermethylation  was 
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associated with increased inflammation and increased mortality in patients with chronic kidney 
disease [39]. 
The pathophysiology of ZDF rats is characterized by obesity, hyperglycemia, 
hyperinsulinemia, hyperlipidemia, and hypertension [40]).  ZDF rats develop hyperinsulinemia 
and insulin resistance before 7 wk of age, with an incremental drop in elevated insulin levels 
around 8 wk of age, and at 12 wk of age blood glucose levels rise, resulting in animals becoming 
overtly diabetic [41].  Although insulin levels continue to decrease due to pancreatic β-cell 
exhaustion, ZDF rats may remain hyperinsulinemic relative to lean controls well into the 
advanced diabetic stage [21], as was observed in this study.  In contrast, chemically-induced type 
1 diabetes also results in hyperglycemia, but is characterized by a lack of insulin production.  
Treatment of rats or hepatic cell lines with glucocorticoids, such as dexamethasone or 
triamcinolone, has also been shown to induce expression of methionine adenosyltransferase 
(MAT), GNMT, BHMT, and CBS at the transcriptional level and insulin administration has been 
shown to prevent these alterations in both rats and/or cell lines [4,11,12,42,43].  Interestingly, 
insulin stimulates transmethylation, and transsulfuration flux in healthy individuals [44].  Insulin 
treatment of untreated HepG2 hepatocarcinoma cells was also capable of inducing MAT activity 
[45]; thus, insulin likely plays a role in the metabolic perturbations observed in the early type 2 
diabetic state.  Treatment of HepG2 cells with glucose also resulted in stimulation of MAT 
activity and induced genomic hypermethylation [45].  Several recent cell culture studies that 
were designed to mimic hyperglycemia have reported histone modifications which persist even 
after restoration of normal glucose concentrations [38,46-48].  Based on genome-wide profiling 
of specific histone modifications, these studies implicate hyperglycemia in the epigenetic 
regulation of pathways involved in signal transduction, oxidative stress, immune function, and 
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inflammation.  The bulk of evidence indicates that aberrations of methyl group metabolism and 
epigenetic regulation are likely due to the combination of hyperglycemia, a lack of insulin or 
insulin resistance, and elevated counter-regulatory hormones. In support of this, we have recently 
demonstrated that insulin administration prevents many of the alterations in methyl group and 
homocysteine metabolism, including the hypomethylation of DNA, in a type 1 diabetes rat 
model [49].  The differential response in our observed changes in methyl group metabolism as a 
function of type 1 vs. type 2 diabetes may reside in differences in metabolic signals that are 
characteristic of each diabetic state.  In both human patients and animal models, C peptide is 
increased in type 2 diabetes, but markedly decreased in type 1 diabetes [49]. C peptide has been 
shown to exhibit a number of insulinomimetic properties, be involved in cell signaling, and has 
been implicated in the development of vascular inflammation and atherosclerosis in type 2 
diabetes [49].  However, the actions of C peptide in type 2 diabetics are largely uncharacterized 
and may provide an opportunity for investigation into the pathological differences between type 
1 and type 2 diabetes, particularly with respect to methyl group metabolism.     
In summary, we have shown that the metabolism of methyl groups and homocysteine 
were altered in a tissue-specific manner during the pathogenesis of type 2 diabetes in the ZDF 
rat.  Although there are many commonalities in the regulation of methyl group and homocysteine 
metabolism in type 1 and type 2 diabetes, the impact on epigenetic regulation (i.e., DNA 
methylation) was divergent between the two diabetic conditions.  Abnormalities of enzymatic 
regulation and key metabolite concentrations have been observed as early as 5 wk of age [9] and 
we have shown hepatic DNA hypermethylation was evident at 12 wk of age in ZDF rats.  Data 
are lacking prior to these time points; thus, it is unclear when abnormalities in methyl group 
metabolism and epigenetic regulation are initiated in the ZDF rat.  However, it is evident that 
Page 17 of 31
http://mc.manuscriptcentral.com/dmrr
Diabetes/Metabolism Research and Reviews - www.interscience.wiley.com/journal/dmrr
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FOR REVIEW ONLY
17 
 
perturbations of methyl group metabolism and aberrant DNA methylation represent early events 
in the pathogenesis of type 2 diabetes with potentially persistent effects owing to the stable 
nature of epigenetic marks.  The role of DNA methylation in diabetes and its potential relation to 
diabetic complications, such as nephropathy [50], is clearly an important and emerging field. 
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Figure Legends 
Figure 1.  Methyl group and homocysteine metabolism.  Enzymes are shown in black boxes, 
whereas vitamin substrates and/or cofactors are shown in gray boxes.   Abbreviations are: 
betaine-homocysteine S-methyltransferase (BHMT); cystathionine β-synthase (CBS); 
dimethylglycine (DMG); methionine synthase (MS); methyltransferases (MTs); 5,10-methylene-
THF reductase (MTHFR); S-adenosylhomocysteine (SAH); S-adenosylmethionine (SAM); 
tetrahydrofolate (THF); and methyl acceptor (X).  Key SAM-dependent methyltransferases 
include: glycine N-methyltransferase (GNMT); phosphatidylethanolamine N-methyltransferase 
(PEMT); and DNA methyltransferase 1 (DNMT1).  These three methyltransferases respectively 
catalyze the conversion of glycine to sarcosine, phosphatidylethanolamine to 
phosphatidylcholine, and cytosine-DNA to 5-methyl-cytosine-DNA .  In addition to THF, this 
series of interrelated pathways are dependent on a number of other B-vitamins, including 
riboflavin (B2), vitamin B6, and vitamin B12. 
 
 
Figure 2.  Hepatic and renal methylation status of genomic DNA in lean (open bars) and ZDF 
(black bars) rats at (A) 12 and (B) 21 wk of age.  Using the method of Pogribny et al [19], 
incorporation of [3H]-dCTP is inversely related to the degree of endogenous methylation.  Values 
are mean ± SEM (n = 6).  *Different from control, P ≤ 0.05.  
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Table 1.  Real-time RT-PCR primers 
Target   Primers (5' → 3') 
GNMT  F*: ACA ACA AAG CCC ACA TGG TAA CCC 
  R: AGC CGA AAC TTA CTG AAG CCA GGA 
PEMT  F: TGT GCT CTC CAG CTT CTA TGC ACT 
  R: AGG GAA ATG TGG TCA CTC TGG ACT 
MS  F: TTG GCC TAC CGG ATG AAC AAA TGC 
  R: AGC CAC AAA CCT CTT GAC TCC TGT 
BHMT  F: ATC TGG GCA GAA GGT CAA TGA AGC 
  R: TGA CTC ACA CCT CCT GCA ACC AAT  
CBS  F: AAC ATG TTG TCC TCC CTG CTT GCT 
  R: TCG GCT TGA ACT GCT TGT AGA GGA 
DNMT1  F: TGT GGC AAG AAG AAA GGT GGC AAG  
  R: TGG ATG GAC TTG TGG GTG TTC TCA  
DNMT3a  F: AGA GTG TCT GGA ACA CGG CAG AAT  
  R: TGC TGG TCT TTG CCC TGC TTT ATG 
DNMT3b  F: TGC GCC TGC AAG ACT TCT TCA CTA  
  R: TGC AGG AAT CGC TGG GTA CAA CTT  
MBD1  F: CCT GCA CCT TTG TGC TGT GAG AAT  
  R: CAG TCT TTG CAC AAT GTC CTG CGT  
MBD2  F: TCA GAA GTA AAC CAC AGC TGG CGA  
  R: ACT AGG CAT CAT CTT GCC GCT TCT  
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MBD3  F: GAA GAA GTT TCG CAG CAA GCC ACA  
  R: CAT CTT TCC CGT GCG GAA ATC GAA  
MBD4  F: AGC TAA ACC TCA GGA CAC GAA GCA  
  R: TTG GAC AGGCTG TTG CTA TCT GGA  
MeCP2  F: GCA GCA GCA TCA GAA GGT GTT CAA  
  R: TGC TTG GAA AGG CAT CTT GAC GAG  
18S  F: GAA CCA GAG CGA AAG CAT TTG CCA  
    R: ATG GTC GGA ACT ACG ACG GTA TCT  
*F denotes forward primer, R denotes reverse primer. 
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Table 2.  Tissue-specific activity and abundance of enzymes regulating methyl group and 
homocysteine metabolism in lean (+/?) and ZDF (fa/fa) rats at 12 and 21 wk of age 
  12 wk 21 wk 
  Tissue Lean ZDF Lean ZDF 
      
GNMT Activity Liver 305 ± 17 381 ± 7* 273 ± 8 324 ± 13* 
(pmol/(min • mg protein))  Kidney 45 ± 1 43 ± 3 54 ± 5 73 ± 3* 
 
Heart n.d. n.d. n.d. n.d. 
      
GNMT Abundance Liver 1.00 ± 0.14 1.65 ± 0.10* 1.00 ± 0.03 1.08 ± 0.02* 
Relative to control Kidney 1.00 ± 0.10 0.80 ± 0.11 1.00 ± 0.07 0.98 ± 0.07 
 
Heart 1.00 ± 0.01 0.99 ± 0.01 1.00 ± 0.04 0.99 ± 0.05 
      
MS activity Liver 416 ± 40 498 ± 21* 541 ± 29  562 ± 40 
(pmol/(min • mg protein))  Kidney 886 ± 47 976 ± 15 809 ± 34  746 ± 22 
 
Heart 375 ± 13 359 ± 7 286 ± 20  343 ± 22* 
      
CBS Abundance Liver 1.00 ± 0.09 1.27 ± 0.05* 1.00 ± 0.09 0.78 ± 0.06* 
Relative to control Kidney 1.00 ± 0.11 0.67 ± 0.11* 1.00 ± 0.08 1.02 ± 0.07 
  
Heart 1.00 ± 0.14 0.81 ± 0.16 1.00 ± 0.03 0.88 ± 0.05* 
 
Data are means ± SEM (n = 4-6).  The abbreviation n.d. indicates activity was not detected.  
Asterisks (*) indicate a significant difference from control, P ≤ 0.05.  
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Table 3.  Hepatic mRNA abundance of enzymes regulating methyl group supply and 
utilization in lean (+/?) and ZDF (fa/fa) rats at 12 and 21 wk of age. 
 
    12 weeks, mean fold induction   21 weeks, mean fold induction 
Target   Lean ZDF   Lean ZDF 
GNMT  1.00 ± 0.55 1.03 ± 0.23  1.00 ± 0.13 1.36 ± 0.16* 
PEMT  1.00 ± 0.40 3.31 ± 1.20  1.00 ± 0.18 1.73 ± 0.21* 
MS  1.00 ± 0.15 1.91 ± 0.58  1.00 ± 0.27 1.30 ± 0.24 
BHMT  1.00 ± 0.49 1.64 ± 0.47  1.00 ± 0.22 2.06 ± 0.54* 
CBS  1.00 ± 0.54 0.77 ± 0.29  1.00 ± 0.28 1.10 ± 0.20 
DNMT1   1.00 ± 0.23 0.97 ± 0.33   1.00 ± 0.29 1.95 ± 0.37* 
 
Data are means ± SEM (n = 4-6).  Asterisks (*) indicate a significant difference from control, P 
≤ 0.05. 
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Table 4.  Fasted plasma and tissue concentrations of total homocysteine in lean (+/?) and 
ZDF (fa/fa) rats. 
Total Homocysteine  
(µM plasma or µmol/g tissue) 
Sample 
source 
Age           
(wk) Lean ZDF 
   
  
Plasma 12 6.8 ± 0.3 2.2 ± 0.1* 
 21 3.6 ± 0.3 1.6 ± 0.1* 
     
Liver 12 155 ± 22 166 ± 10 
 21 168 ± 7 203 ± 20 
     
Kidney 12 11.0 ± 4.1 4.1 ± 0.7* 
 21 6.3 ± 0.9 3.2 ± 1.1* 
        
 
Data are means ± SEM (n = 4-6).  Asterisks (*) indicate a significant difference from control, P 
≤ 0.05. 
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